Skip to content
DataLookout
Menu

NCT07262983

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 222 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria changed
    • Start date: Nov 24, 2026 to Nov 25, 2026
  2. Notable Eligibility criteria expanded, about 10 words
    • Start date: Nov 23, 2026 to Nov 24, 2026
    • Study description shortened, about 3 words
  3. Minor Start date: Nov 22, 2026 to Nov 23, 2026
  4. Minor Start date: Nov 19, 2026 to Nov 22, 2026
  5. Minor Start date: Nov 18, 2026 to Nov 19, 2026
Show 45 earlier versionsHide 45 earlier versions
  1. Minor Start date: Nov 17, 2026 to Nov 18, 2026
  2. Minor Start date: Nov 15, 2026 to Nov 17, 2026
  3. Minor Start date: Nov 12, 2026 to Nov 15, 2026
  4. Minor Start date: Nov 11, 2026 to Nov 12, 2026
  5. Minor Start date: Nov 10, 2026 to Nov 11, 2026
  6. Minor Start date: Nov 9, 2026 to Nov 10, 2026
  7. Minor Start date: Nov 8, 2026 to Nov 9, 2026
  8. Minor Start date: Nov 5, 2026 to Nov 8, 2026
  9. Minor Start date: Nov 4, 2026 to Nov 5, 2026
  10. Minor Start date: Nov 3, 2026 to Nov 4, 2026
  11. Minor Start date: Nov 2, 2026 to Nov 3, 2026
  12. Minor Start date: Nov 1, 2026 to Nov 2, 2026
  13. Minor Start date: Oct 29, 2026 to Nov 1, 2026
  14. Minor Start date: Oct 28, 2026 to Oct 29, 2026
  15. Minor Start date: Oct 27, 2026 to Oct 28, 2026
  16. Minor Start date: Oct 26, 2026 to Oct 27, 2026
  17. Minor Start date: Oct 25, 2026 to Oct 26, 2026
  18. Minor Start date: Oct 22, 2026 to Oct 25, 2026
  19. Minor Start date: Oct 21, 2026 to Oct 22, 2026
  20. Minor Start date: Oct 20, 2026 to Oct 21, 2026
  21. Minor Start date: Oct 19, 2026 to Oct 20, 2026
  22. Minor Start date: Oct 18, 2026 to Oct 19, 2026
  23. Minor Start date: Oct 14, 2026 to Oct 18, 2026
  24. Minor Start date: Oct 13, 2026 to Oct 14, 2026
  25. Minor Start date: Oct 12, 2026 to Oct 13, 2026
  26. Minor Start date: Oct 11, 2026 to Oct 12, 2026
  27. Minor Start date: Oct 8, 2026 to Oct 11, 2026
  28. Minor Start date: Oct 7, 2026 to Oct 8, 2026
  29. Minor Start date: Oct 6, 2026 to Oct 7, 2026
  30. Minor Start date: Oct 5, 2026 to Oct 6, 2026
  31. Minor Start date: Oct 4, 2026 to Oct 5, 2026
  32. Notable Eligibility criteria expanded, about 53 words Show 4 more changesShow less
    • Start date: Sep 20, 2026 to Oct 4, 2026
    • Secondary endpoints: details revised at 1 of 10 entries
    • Study description expanded, about 25 words
    • Publications: details revised at 3 of 3 entries
  33. Minor Start date: Sep 17, 2026 to Sep 20, 2026v185
  34. Minor Start date: Sep 16, 2026 to Sep 17, 2026v184
  35. Minor Start date: Sep 15, 2026 to Sep 16, 2026v183
  36. Minor Start date: Sep 14, 2026 to Sep 15, 2026v182
  37. Minor Start date: Sep 10, 2026 to Sep 14, 2026v181
  38. Minor Start date: Sep 9, 2026 to Sep 10, 2026v180
  39. Minor Start date: Sep 8, 2026 to Sep 9, 2026v179
  40. Minor Start date: Sep 7, 2026 to Sep 8, 2026v178
  41. Minor Start date: Sep 6, 2026 to Sep 7, 2026v177
  42. Minor Start date: Sep 3, 2026 to Sep 6, 2026v176
  43. Minor Start date: Sep 2, 2026 to Sep 3, 2026v175
  44. Minor Start date: Sep 1, 2026 to Sep 2, 2026v174
  45. Minor Start date: Aug 31, 2026 to Sep 1, 2026v173
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of SAEs, AEs requiring study drug discontinuation.
Timeframe: Through end of study

Secondary (10)

Incidence of Candida and/or bacterial infections.
Mean change in CLASI score from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in EASI score from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in SLEDAI score from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in the PGA score from day -90 to day 0 and then from day 0 to days 90 and 180.
Show 5 moreShow less
Mean change in the SF-36 score (adults) from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in the PROMIS score from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in the DLQI score (adults) from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in the CDLQI score (pediatrics) from day -90 to day 0 and then from day 0 to days 90 and 180.
Mean change in the PedsQL score (pediatrics) from day -90 to day 0 and then from day 0 to days 90 and 180.

Arms and interventions

InterventionalExperimental

baricitinib

Drugs: baricitinib

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States